CAR-T Cell Therapy for Gastric Cancer in China
In June 2026, China's NMPA approved satricabtagene autoleucel (Kailimei) — the first CAR-T cell therapy approved anywhere in the world for a solid tumor. It targets CLDN18.2, a protein found on some advanced gastric and gastroesophageal junction (GEJ) cancers.
Why solid tumors were the hard problem
CAR-T therapy has worked well against blood cancers for a decade, but solid tumors like gastric cancer have resisted it: the tumor forms a physical and chemical environment that is harder for engineered T-cells to penetrate and survive in, and there are fewer truly tumor-specific surface targets to engineer against without harming healthy tissue. CLDN18.2 is one of the first solid-tumor targets to clear that bar at regulatory-approval level.
Who this is for
| Product | Manufacturer | Approved for |
|---|---|---|
| Kailimei (satricabtagene autoleucel) | CARsgen Therapeutics | CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma, after failure of at least two prior lines of therapy (approved June 2026) |
Eligibility requires biomarker testing confirming CLDN18.2 positivity and HER2-negative status on a tumor sample — this is one of the first things our reviewing oncologist will check when you send your pathology report.
What's genuinely new here, and what isn't yet known
Because this is the newest approval in our table, the track record is shorter than for the CD19 and BCMA products that have been used for several years. We will always tell you explicitly how recent a given approval is and what that means for the depth of long-term outcome data — durability of response in solid tumors is an active area of follow-up, and your reviewing physician will discuss this with you directly rather than overstate it.
A genuinely new option, treated with appropriate caution
We do not oversell a newly approved therapy. If CLDN18.2 CAR-T is a plausible option for you, we will say so and explain exactly what evidence currently exists. If it is not, or if a clinical trial elsewhere may be a better fit, we will say that instead.
Next step
Send your tumor pathology report (including CLDN18.2 and HER2 testing, if available) and treatment history for a free eligibility review. Start your case review →